Eden Bio, a London, UK-based biotech startup that uses machine learning to increase protein yield, has raised £1 million ($1.17 million) from a seed investment round.
The round was led by SynBioVen, with participation from Dhyan Capital, Saras Capital, and sustainability investor Stefano Bernardi. Additional investment comes from a consortium of angels, including Noor Shaker, Sandra Blewitt, Kevin Mascarenhas, and Andy Russell.
This funding will enable Eden Bio to strengthen its R&D capacity and ability to expand the underlying machine-learning platform over the coming years.
Founder and CEO of Eden Bio, Christopher Reynolds, said: “Eden Bio is on a mission to tackle the low yield and scale-up challenges commercial protein production faces. I’m hugely proud of the results my team has already achieved, and the amazing investors joining us are the perfect complement of commercial, synthetic biology, and AI expertise for Eden Bio, helping us move even faster.”
By using artificial intelligence to genetically optimize microorganism strains, Eden Bio improves the yield of protein products.
Company: Eden Bio Ltd
Round: Seed Round
Funding Month: November 2022
Lead Investors: SynBioVen
Additional Investors: Dhyan Capital, Saras Capital, Stefano Bernardi, Noor Shaker, Sandra Blewitt, Kevin Mascarenhas, and Andy Russell
Company Website: https://eden.bio/
Software Category: Machine Learning driven Strain Optimization
About the Company: Founded in 2021, Eden Bio is a strain-engineering company with the mission of supporting the needs of fermentation businesses. With the world needing to move away from traditional farming methods and into a more sustainable future, Eden Bio is there to help companies make that transition. Through the use of their proprietary machine-learning platform, the team at Eden Bio is able to optimize the genetic modifications made to customer strains. Working across industries, they help companies optimize for yield, enzymatic activity, and more.